HDX

Natural health product licensed in Canada

Other names

Vision HD, VisionHD-98%

Licence holder

Voyageur Pharmaceuticals Ltd.

NPN or DIN-HM

80108077

Status

Active licence

Licence date

10 February 2021

Revision date

9 May 2024

Form

Poudre pour suspension

Route of administration

Orale

Application type

Non traditionnelle

If this product were sold in France

No point flagged by the rules we apply.

A daily quantity is calculated only for an explicit adult oral dosage, stated per day and in a solid unit matching the product form. Ambiguous units, liquids, powders and paediatric doses are not extrapolated. A quantity not calculated is not compared with dose limits. This analysis does not constitute authorisation for sale in France or an assessment of safety or efficacy.

Composition

Non-medicinal ingredients

Ethyl maltol, Stéarate de PEG-20 glycéryle, Sorbitol, Sacharinate de sodium, Vanille, Siméthicone, Carraghénine de sodium, Citrate de sodium

Recommended doses in Canada

Uses authorised in Canada

Double contrast radiography of the esophagus, stomach and duodenum. For use as a radiological contrast medium for upper and lower gastrointestinal procedures by conventional X-Ray and computed tomography (CT).

A use authorised in Canada is not an authorised health claim in the European Union. See the health claims register.

Warnings in Canada

• Précautions et mises en garde

  For professional use only. Do not store after mixing. Diagnostic procedures that involve the use of radiopaque contrast agents should be carried out under the direction of personnel with the requisite training and with a thorough knowledge of the particular procedure to be performed. A history of bronchial asthma, atopy, as evidenced by hay fever and eczema, or a previous reaction to a contrast agent, warrant special attention. Caution should be excerised with the use of radiopaque media in severly debilitated patients and in those with marked hypertension or advanced cardiac disease. Ingestion of barium is not recommended in patients with a history of food aspiration. If barium swallow studies are required in these patients or in patients in whom integrity of the swallowing mechanism is unknown, proceed with caution. Administer initially small amounts such as a half-teaspoon of low-density barium and carefully observe swallowing under fluoroscopic control. If barium is aspired into the larynx, further administartion of barium should be immediately discontinued. If no aspiration is noted, additional barium may be given with continued fluoroscopic monitoring for aspiration. After any barium study of the G.I. tract, it is important to rehydrate the patient as quickly as possible to prevent impaction of barium. To prevent barium impaction, the colon may also require the use of cathartics following the completion of the examination. Saline cathartics are recommended on a routine basis and especially in patients with a history of constipation unless clinically contraindicated. Usage in Pregnancy: Radiation is known to cause harm to the unborn fetus exposed in utero. Therefore, radiographic procedures should only be used when, in the judgement of the physician, its use is deemed essential to the welfare of the pregnant patient. Safe use of barium sulfate in pregnant is not established.

Source

Official Health Canada record, licence 80108077

The formula sold in Europe under the same name may differ. This information does not replace advice from a doctor or pharmacist.

List in the official revision dated 9 May 2024 (register: Licensed Natural Health Products Database (LNHPD), Health Canada: licensed products, ingredients, doses, uses and risks).

List recorded in 2024. Photograph the packaging to check whether it has changed.

Has the product changed? Photograph the packaging.